References
- Jones RN. Antimicrobial activity, spectrum and pharmacokinetic of old and new orally administered cephems. Antimicrob Newsl 1988; 5: 1–7.
- Barry AL, Jones RN. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates. Pediatr Infect Dis J 1987; 6: 954–957.
- Neu HC. In vitro activity of a new broad spectrum, beta-lactamase stable oral cephalosporin, cefixime. Pediatr Infect Dis J 1987; 6; 958–962.
- Brodgen Rex N, Campoli-Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs, 1988; 38: 524–550.
- Bauernfeind A. A new generation of oral cephalosporins: cefixime (FK 027) in vitro activity against isolates from West Germany. In Moellering RC Jr. and Shimada K., eds. Proceedings of a workshop of 14th International Congress of Chemotherapy, Kyoto 1985; 11–16.
- Brittain DC, Scully BE, Hirose T, Neu HC. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther 1985; 38: 590–694.
- Nakashina M, Uematsu T, Takiguchi Y, Kanemare M. Phase I Study of cefixime a new oral cephalosporin. J Clin Pharmacol 1987; 27: 425–431.
- Faulkner RD, Bohaychuk W, Desjardinis RE, et al. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J Clin Pharmacol 1987; 27: 807–812.
- National Commitee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-Second Edition M7-A2. Villanova, (PA), 1990.
- Debbia EA, Pesce A, Schito GC. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother 1988; 32: 279–281.
- Molinari G, Bandelloni R, Paglia P, Debbia EA, Schito GC. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone. Diagn Microbiol Infect Dis 1989; 12: 53s-56s.
- Paglia P, Molinari G, Pesce A, Debbia EA. Dactimicin, a new aminoglycoside: in vitro activity, post-antibiotic effect, and interaction with other antibiotics. Eur J Clin Microbiol Infect Dis 1989; 639–643.
- Jorgensen JH, Redding JS, Maher LA, Howell AW. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol 1987; 25: 2105–2113.
- Pearson RD, Steigbigel RT, Davis HT, Chapman SW. Method for reliable determination of minimal lethal antibiotic concentration. Antimicrob Agents Chemother 1980; 18: 699–708.
- Greenwood D, O’Grady F. An in vitro model of the urinary bladder. J Antimicrob Chemother 1984; 14: 309–311.
- Matsen JM. Antimicrobial susceptibility tests: laboratory testing in support of antimicrobial therapy. In Sonnenwirth AC, Jarett L, eds. Gradwohl’s clinical laboratory methods and diagnosis. St. Louis, 1980; 1937–1970.
- Norden CW. Problems in determination of antimicro-bial synergism in vitro. Rev Infect Dis 1982; 4: 276–281.
- Eagle H, Musselraann A. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88: 99–131.
- Moellering RC Jr. Antimicrobial synergism — an elusive concept. J Infect Dis 1979; 140: 639–641.
- Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interaction of vancomycin plus rifampin versus methicillin-susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26: 220–223.
- Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev 1988; 2: 139–156.
- Krogstag DJ, Moellering RC Jr. Antimicrobial combinations. In Lorian V. ed. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins, 1991: 432–492.
- Shigi Y, Matsumoto Y, Kaizu M, Fujishita Y, Kojo H. Mechanism of action of the new orally administered cephalo-sporin FK027. J Antibiot 1984; 37: 790–796.